TRK FUSION CANCER

Updated Vitrakvi® (larotrectinib) Sub-Analysis at ATA 2021 Supports Efficacy and Safety in Adult and Pediatric TRK Fusion Thyroid Cancer Patients

Retrieved on:

Monday, October 4, 2021

Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), TRK FUSION CANCER, ONCOLOGY AT BAYER, BAYER

Updated thyroid sub-analysis of 29 adult and pediatric TRK fusion cancer patients, of which 28 were evaluable, treated with Vitrakvi (larotrectinib) showed notable overall response rates (ORR) and duration of response (DoR).

Key Points:

Updated thyroid sub-analysis of 29 adult and pediatric TRK fusion cancer patients, of which 28 were evaluable, treated with Vitrakvi (larotrectinib) showed notable overall response rates (ORR) and duration of response (DoR).
These data in patients with thyroid cancer further underscore the importance of integrating biomarker-driven oncology medicines into cancer care, so that appropriate patients can potentially benefit from a targeted treatment approach.
TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing a chimeric TRK protein.
These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.

Latest Analyses of Vitrakvi® (larotrectinib) Support Consistently Meaningful Clinical Profile for Both Adult and Pediatric Patients with TRK Fusion Cancer

Retrieved on:

Thursday, September 16, 2021

Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Vitrakvi® (larotrectinib), TRK Fusion Cancer, Oncology at Bayer, Bayer, VITRAKVI® (LAROTRECTINIB), TRK FUSION CANCER, ONCOLOGY AT BAYER, BAYER

The long-term data for Vitrakvi continue to support consistent responses and similar safety profile seen with the addition of new patients and with longer follow-up.

Key Points:

The long-term data for Vitrakvi continue to support consistent responses and similar safety profile seen with the addition of new patients and with longer follow-up.
In patients who received Vitrakvi following one line of systemic therapy (n=59), the ORR was 73% (95% CI 6084).
TRK fusion cancer occurs when an NTRK gene fuses with another unrelated gene, producing a chimeric TRK protein.
These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.

Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate Strong Clinical Profile in Patients with TRK Fusion Cancer Regardless of Tumor Type and Age

Retrieved on:

Wednesday, May 19, 2021

In addition, an intra-patient pooled retrospective analysis assessing the treatment effect of Vitrakvi in patients with TRK fusion cancer previously treated with one or more line of therapy were presented.

Key Points:

In addition, an intra-patient pooled retrospective analysis assessing the treatment effect of Vitrakvi in patients with TRK fusion cancer previously treated with one or more line of therapy were presented.
Two percent of patients discontinued Vitrakvi due to TRAEs and no treatment-related deaths were reported.\nData for the integrated dataset were pooled from three Vitrakvi clinical trials (NCT02122913, NCT02576431 and NCT02637687) in adult and pediatric patients with TRK fusion cancer.
These TRK fusion proteins are oncogenic drivers promoting cell growth and survival, leading to TRK fusion cancer.
Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer \xe2\x80\x93 an expanded dataset [abstract].